-
Published 2/1/2025
Pickering RT, Asundi A, Olson A, Soden K, Kuritzkes DR, Lin NH. Increased insulin resistance following switch from efavirenz to cobicistat-boosted elvitegravir. Antivir Ther. 2025 Feb; 30(1):13596535251314571. PMID: 39953931.
-
Published 11/22/2024
Lilie T, Bouzy J, Asundi A, Taylor J, Roche S, Olson A, Coxen K, Corry H, Jordan H, Clayton K, Lin N, Tsibris A. HIV-1 latency reversal agent boosting is not limited by opioid use. JCI Insight. 2024 Nov 22; 9(22). PMID: 39470739.
-
Published 5/15/2024
Pihl RMF, Smith-Mahoney EL, Olson A, Yuen RR, Asundi A, Lin N, Belkina AC, Snyder-Cappione JE. Vd1 Effector and Vd2 ?d T-Cell Subsets Shift in Frequency and Are Linked to Plasma Inflammatory Markers During Antiretroviral Therapy-Suppressed HIV Infection. J Infect Dis. 2024 May 15; 229(5):1317-1327. PMID: 38390982.
-
Published 6/3/2023
Lilie T, Bouzy J, Asundi A, Taylor J, Roche S, Olson A, Coxen K, Corry H, Jordan H, Clayton K, Lin N, Tsibris A. Opioid use does not limit potent low-dose HIV-1 latency reversal agent boosting. medRxiv. 2023 Jun 03. PMID: 37398278.
-
Published 1/10/2022
Asundi A, Olson A, Jiang W, Varshney SP, White LF, Sagar M, Lin NH. Integrase Inhibitor Use Associated with Weight Gain in Women and Incident Diabetes Mellitus. AIDS Res Hum Retroviruses. 2022 03; 38(3):208-215. PMID: 34877881.